NERV Profile
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for central nervous system (CNS) disorders. Headquartered in Waltham, Massachusetts, Minerva focuses on addressing unmet medical needs in the field of neurology and psychiatry through its advanced research and development programs.
The company's primary product candidate, roluperidone, is being developed for the treatment of schizophrenia. This novel antipsychotic agent is designed to target multiple neurotransmitter systems, potentially offering a new therapeutic option for patients with this complex and challenging condition. Minerva has entered into a licensing agreement with Mitsubishi Tanabe Pharma Corporation, which grants Mitsubishi the rights to develop, sell, and import roluperidone outside of Asia, leveraging its global expertise to advance the drug's commercial potential.
In addition to roluperidone, Minerva is advancing MIN-301, a soluble recombinant form of the neuregulin-1b1 protein. This therapeutic candidate is aimed at treating Parkinson's disease and other neurodegenerative disorders. MIN-301's mechanism involves modulating neurotrophic factors, which are critical for neuronal survival and function, thus offering potential benefits in managing progressive neurological diseases.
Founded in 2007 as Cyrenaic Pharmaceuticals, Inc., the company rebranded as Minerva Neurosciences, Inc. in 2013 to better reflect its focus on neurological and psychiatric conditions. Minerva's commitment to advancing CNS therapeutics is underscored by its robust pipeline and strategic partnerships, positioning it as a key player in the pursuit of innovative treatments for some of the most challenging neurological and psychiatric disorders.
|
